皮下脂膜炎样T细胞淋巴瘤1例

报道1例皮下脂膜炎样T细胞淋巴瘤。患者女，34岁。全身反复出现肿块、结节性损害1年。4个月前部分肿块破溃，伴发热、乏力、贫血等症状。皮损组织病理显示皮下脂肪层的淋巴细胞、组织细胞浸润，脂膜炎样T细胞瘤。免疫组化证明下细胞来源，伴有TCRγ基因克隆性重排，诊断为脂膜炎样T细胞瘤。     

皮下脂膜炎样T细胞淋巴瘤1例

皮下脂膜炎样T细胞淋巴瘤临床上较少见,属于原发性皮肤淋巴瘤,病变主要累及皮下脂肪,呈脂膜炎样的原发性外周T细胞淋巴瘤.组织病理学改变为脂膜炎样异形淋巴细胞浸润,常伴有噬血细胞综合征,病情进展快,死亡率高.现将我科诊治的1例报告如下.     

儿童皮下脂膜炎样T细胞淋巴瘤并发噬血细胞综合征一例

正皮下脂膜炎样T细胞淋巴瘤(subcutaneous panniculitis-like T-cell lymphoma,SPTCL)是一种原发于皮肤的外周T细胞淋巴瘤,主要累及皮下脂肪组织。本病临床少见,常伴噬血细胞综合征(hemophagocytic syndrome,HPS),预后差。笔者收治1例长期随访的皮下脂膜炎样T细胞淋巴瘤并先后两次在EB病毒感染活动期出现噬血细胞综合征的     

脂膜炎样T细胞淋巴瘤1例

报告1例皮下脂膜炎样T细胞淋巴瘤,患者女,44岁,左侧臀部出现红肿、结节,伴疼痛和发热半个月,皮损组织病理检查：皮下脂肪层有淋巴细胞、组织细胞浸润,免疫组化证明浸润淋巴细胞为T细胞来源,组织病理改变符合脂膜炎样T细胞淋巴瘤。     

皮下脂膜炎样T细胞淋巴瘤研究进展

皮下脂膜炎样T细胞淋巴瘤是指主要累及皮下脂肪细胞且与脂膜炎相似的一种原发于皮肤的外周T细胞淋巴瘤。本文对其临床特点、组织病理学特点、实验室检查、组织学来源,与EB病毒感染的关系、治疗及预后、诊断及鉴别诊断综述如下。     

皮肤γδ-T细胞淋巴瘤临床和组织病理特征

皮肤γδ-T细胞淋巴瘤是指瘤细胞起源于γδ-T细胞的一组Epstein-Barr病毒阴性的皮肤外周T细胞淋巴瘤。其病程呈侵袭性，预后差。皮肤损害主要发生于上、下肢，偶或泛发，累及躯干，常表现为蕈样肉芽肿样斑块、皮下结节或溃疡性肿瘤。同一患者常出现一种以上的组织病理模式[向表皮性、侵犯真皮和(或)皮下脂肪组织]。瘤细胞多形提示T细胞受体γ或δ基因重排，表达CD^4-、CD8^-，成熟细胞毒性表型，偶或CD8^ 表型；常伴坏死和(或)细胞凋亡。     

EB病毒感染相关性皮肤淋巴瘤

Epstein-BarrVirus（EBV）正常成年人群感染率达95%以上,其可以感染B细胞、T细胞、NK细胞以及上皮细胞,分为潜伏感染和增殖感染。EBV相关性皮肤病有NK/T细胞淋巴瘤,皮下脂膜炎样T细胞淋巴瘤,慢性活动性EB病毒感染,种痘样水疱病,种痘样皮肤T细胞淋巴瘤,蚊虫叮咬过敏症,传染性单核细胞增多症等,特别是鼻/鼻型结外NK/T细胞淋巴瘤、皮下脂膜炎样T细胞淋巴瘤和种痘样皮肤T细胞淋巴瘤较为严重,治疗效果不佳,死亡率高。     

尖锐湿疣患者外周血T细胞抗原受体γδ T细胞的检测

目的：探讨外周血T细胞抗原受体（TCR）γδT细胞在尖锐湿疣发病机制中的作用。方法：采用双色荧光抗体染色技术经流式细胞仪检测20例尖锐湿疣患者外周血TCRγδT细胞与TCRαβT细胞的百分率。结果：尖锐湿疣患者外周血中TCRγδT细胞百分率比正常对照组显著增高（P＜0．01），TCRαβT细胞的百分率与正常对照组相比差异无显著性（P＞0．05）。结论：尖锐湿疣患者外周血TCRγδT细胞数量增多是机体在受到病毒感染时的一种早期非特异性免疫反应，在尖锐湿疣的发病机制中起一定的免疫防卫作用。     

皮下脂膜炎样T细胞淋巴瘤1例

报告1例皮下脂膜炎样T细胞淋巴瘤。患者女,34岁。四肢出现疼痛性红斑、结节9年,伴有发热、消瘦等。组织病理学改变主要在皮下脂肪组织内,可见瘤细胞浸润于脂肪细胞间。免疫组化显示瘤细胞表达CD45Ro及CD68,不表达CD20。     

皮下脂膜炎样T细胞淋巴瘤并嗜血细胞综合征和股静脉栓塞1例

皮下脂膜炎样T细胞淋巴瘤(subcutaneous panniculitis-like T-cell lymphoma, SPTCL)是一种少见的原发性皮肤T细胞淋巴瘤,临床和病理上有时被误诊为脂膜炎,如病程中出现嗜血细胞综合征(hemophagocytic syndrome,HPS),患者病情迅速恶化,死亡率高.现将我科诊治的1例SPTCL报道如下.     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Multiple New-Onset Subcutaneous Nodules of the Upper Extremity Digits: Giant Cell Tumor of Tendon Sheath and Lipoma

A black woman with the concurrent onset of two subcutaneous nodules located on the digits of her upper extremities is described. Initially, a single systemic disorder was considered; yet, the lesions differed in morphology and consistency. Microscopic examination of the nodules showed a giant cell tumor of tendon sheath and a lipoma. Although Occam's “razor” suggests that multiple lesions in the same person are more likely to represent variable manifestations of a single disorder than several different diseases in that individual, the simultaneously appearing lesions in this patient represented two different conditions.